Companies /Healthcare

Charles River Laboratories International Inc

NYSE: CRL Diagnostics & Research
$291.50
▼ $4.91 (−1.66%) today
Markets closed · 1:25am ET
24/7 Rating BUY
12-Month Price Target
$314.83 +7.6% upside

Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets →

Current close $292.72
Street consensus $281.00
Ours vs. the Street +12.0%
$259.33Conservative$292.72Current$314.83Our Target$329.47Optimistic
12-Month Projection Historical Optimistic Target Conservative
$180$240$300Aug 2025Aug 2027Today$329.47$314.83$259.33
$180$240$300Aug 2025Aug 2027Today$329.47$314.83$259.33

Analyst Sentiment

16ANALYSTS
Buy1275%
Hold319%
Sell16%
The Bottom Line

Charles River Laboratories appears attractively valued at current levels. With a 7.6% upside to our $314.83 target, the risk-reward profile looks favorable for investors with a 12-month time horizon. Wall Street agrees, with 75% of analysts rating it a Buy.

The 24/7 Factor

Base Growth
Conservative growth baseline (reduced to avoid double-counting P/E growth)
1.05×
Sector Momentum
Defensive growth with aging population tailwinds
1.10×
Analyst Consensus
Strong analyst consensus (bullish)
+4.1%
Earnings Growth
Earnings pressure
−1.7%
Volatility Adjustment
Higher volatility stock
−0.8%
Price Position
Upper range of 52-week trading
+0.5%
Read our full methodology →

5-Year Projection

Long-Term Forecast Optimistic Target Conservative
$250$300$350$400’26’27’28’29’30’31$416.61$394.96$269.84
$250$300$350$400’26’27’28’29’30’31$416.61$394.96$269.84

Prediction History

CRL Price Target History Our Target Stock Price
$200$240$280$320Jun 4Aug 21$312.53$295.19
$200$240$280$320Jun 4Aug 21$312.53$295.19
Date Price Target Stock Price Rating Upside
$312.53 $295.19 BUY +5.9%
$304.22 $280.05 BUY +8.6%
$274.11 $267.49 HOLD +2.5%
$252.70 $228.50 BUY +10.6%
$247.09 $229.29 BUY +7.8%
$251.68 $224.89 BUY +11.9%
$245.43 $233.60 BUY +5.1%
$245.47 $230.69 BUY +6.4%

Frequently Asked Questions

What is the CRL stock price prediction for 2030?

Looking ahead to 2030, our model projects CRL could trade at an average price of $371.99, with a potential range between $278.99 and $464.99. This represents a potential 27.1% return from today’s price. Long-term forecasts depend heavily on company execution, competitive dynamics, and broader market conditions.

Is CRL a buy, sell, or hold right now?

24/7 Wall St. currently rates CRL as a BUY. Moderate upside (+7.6%) Among Wall Street analysts, 12 rate it Buy, 3 rate it Hold, and 1 rate it Sell.

What is the CRL stock price target in an optimistic scenario?

In our optimistic scenario for CRL, the stock could reach $329.47 over the next 12 months, representing a 12.6% gain from today’s price. This scenario assumes favorable conditions materialize, including strong earnings growth, positive market sentiment, and successful execution of company initiatives.

What is the downside risk for CRL stock?

In our conservative scenario, CRL could trade as low as $259.33 over the next 12 months, representing a 11.4% decline from current levels. This scenario accounts for potential headwinds including earnings misses, competitive pressures, or broader market weakness.

Projections are estimates based on current data, updated daily. Not investment advice. Learn how we calculate these projections →